Human Cadherin 13 quantitates human Cadherin 13 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Cadherin 13.
Human Cadherin 13 quantitates human Cadherin 13 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Cadherin 13.
Human Cadherin 13 quantitates human Cadherin 13 in serum, plasma, supernatant. The assay will exclusively recognize both natural and recombinant human Cadherin 13.
The protein encoded by this gene has a C-terminal domain with deendoribonuclease treatment activity of the tRNA 3, which catalyzes the elimination of the 3-tail of the precursor tRNA. The protein also interacts with the activated member of the Smad 2 family (Smad2) and its nuclear partner Forkhead Box H1 (also known as FAST-1), and a reduced expression can suppress the transformation of growth arrest induced by beta growth factor. The mutations of this gene lead to an increased risk of prostate cancer. Several transcription variants coding different isoforms were found for this gene.
Sensitivity
Sensitivity of the dosage: 40 pg/ml.
Measurement range
Dosing range: 40 to 10,000 pg/ml.
Duration of dosing
Total duration of dosing: 4 h 45 min.
Target
Target: H-Cadherin.
Samples
Type of sample: Plasma, Serum, Surnatant (Serum volume, 50 µl; plasma, 50 µl; supernatant, 50 µl).